<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>16(6)</volume><submitter>Schirwani-Hartl N</submitter><pubmed_abstract>Infections with severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) in pregnancy are associated with the development of preeclampsia and fetal growth restriction (FGR). Recently, preeclampsia was linked to impaired maternal hemodynamic function. This retrospective study evaluated singleton pregnancies with COVID-19 during pregnancy and healthy pregnant controls matched for gestational age from November 2020 to March 2022. Non-invasive assessment of maternal hemodynamics by continuous wave Doppler ultrasound measurements (USCOM-1A&lt;sup>®&lt;/sup> Monitor) and oscillometric arterial stiffness (Arteriograph) was performed. Overall, 69 pregnant women were included-23 women after COVID-19 during pregnancy and 46 healthy controls. While two women (8.7%) were admitted to the hospital due to COVID-19-related symptoms, none required intensive care unit admission or non-invasive/invasive ventilation. There were no statistically significant differences in the majority of hemodynamic parameters between the two cohorts. The prevalence of FGR was significantly higher in the COVID-19 during pregnancy group (9.5% vs. healthy controls: 0.0%; &lt;i>p&lt;/i> = 0.036), especially in nulliparous women. No difference in angiogenic markers and neonatal outcomes were observed between pregnant women after COVID-19 and healthy controls. In conclusion, no significant differences in hemodynamic parameters or neonatal outcome were observed in women with COVID-19 during pregnancy. However, an increased prevalence of FGR could be described.</pubmed_abstract><journal>Viruses</journal><pagination>868</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11209264</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>The Impact of COVID-19 during Pregnancy on Maternal Hemodynamic Function, Angiogenic Markers and Neonatal Outcome.</pubmed_title><pmcid>PMC11209264</pmcid><pubmed_authors>Berger A</pubmed_authors><pubmed_authors>Binder J</pubmed_authors><pubmed_authors>Tschanun L</pubmed_authors><pubmed_authors>Palmrich P</pubmed_authors><pubmed_authors>Perkmann-Nagele N</pubmed_authors><pubmed_authors>Haberl C</pubmed_authors><pubmed_authors>Schirwani-Hartl N</pubmed_authors><pubmed_authors>Kiss H</pubmed_authors></additional><is_claimable>false</is_claimable><name>The Impact of COVID-19 during Pregnancy on Maternal Hemodynamic Function, Angiogenic Markers and Neonatal Outcome.</name><description>Infections with severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) in pregnancy are associated with the development of preeclampsia and fetal growth restriction (FGR). Recently, preeclampsia was linked to impaired maternal hemodynamic function. This retrospective study evaluated singleton pregnancies with COVID-19 during pregnancy and healthy pregnant controls matched for gestational age from November 2020 to March 2022. Non-invasive assessment of maternal hemodynamics by continuous wave Doppler ultrasound measurements (USCOM-1A&lt;sup>®&lt;/sup> Monitor) and oscillometric arterial stiffness (Arteriograph) was performed. Overall, 69 pregnant women were included-23 women after COVID-19 during pregnancy and 46 healthy controls. While two women (8.7%) were admitted to the hospital due to COVID-19-related symptoms, none required intensive care unit admission or non-invasive/invasive ventilation. There were no statistically significant differences in the majority of hemodynamic parameters between the two cohorts. The prevalence of FGR was significantly higher in the COVID-19 during pregnancy group (9.5% vs. healthy controls: 0.0%; &lt;i>p&lt;/i> = 0.036), especially in nulliparous women. No difference in angiogenic markers and neonatal outcomes were observed between pregnant women after COVID-19 and healthy controls. In conclusion, no significant differences in hemodynamic parameters or neonatal outcome were observed in women with COVID-19 during pregnancy. However, an increased prevalence of FGR could be described.</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 May</publication><modification>2025-04-04T21:22:36.476Z</modification><creation>2025-04-04T21:22:36.476Z</creation></dates><accession>S-EPMC11209264</accession><cross_references><pubmed>38932160</pubmed><doi>10.3390/v16060868</doi></cross_references></HashMap>